Twist Bioscience posts record quarterly revenue of $126.6 million in 2026
Key Facts
Twist Bioscience reported results on November 12 for the fourth quarter and fiscal year ended September 30, 2026, posting record quarterly revenue of $126.6 million. Revenue rose 28% from $99.0 million in the same quarter of the prior fiscal year, marking 15 consecutive quarters of sequential growth. The company said results included growth in its DNA synthesis and protein solutions business and in gene sequencing applications. It also recorded a smaller net loss than in the comparable period and positive adjusted earnings before interest, taxes, depreciation and amortization. Shares closed at $122.59 on November 11, before the results were announced, after closing at $132.13 in the previous session.
The quarterly net loss was $20.6 million, or $0.32 per diluted share, compared with $27.1 million and $0.45 per share in the fourth quarter of fiscal 2025. Gross margin rose to 53.1% from 51.3% a year earlier, signaling improved profitability on sales during the quarter. Adjusted earnings before interest, taxes, depreciation and amortization turned positive at $2.2 million, compared with an adjusted loss of $7.8 million in the year-earlier period. By business unit, revenue from DNA synthesis and protein solutions rose 33% to $61.0 million. Revenue from gene sequencing applications increased 24% to $65.7 million.
For fiscal 2026, revenue reached a record $459.4 million, up 22% from $376.6 million in fiscal 2025. But sales growth did not prevent the annual loss from widening: net loss was $130.2 million, or $2.08 per diluted share, compared with a loss of $77.7 million and $1.30 per share in the prior year. The company shipped products to about 4,100 customers during the year, compared with about 3,800 in fiscal 2025. As of September 30, cash and cash equivalents and short-term investments totaled about $582 million. The chief executive said the company is entering fiscal 2027 with a stronger business and capital to invest in its next phase of growth, linking opportunities to the expanding range of what scientists can design using artificial intelligence and rising demand for unique molecules in personalized medicine.
The company expects fiscal 2027 revenue of between $550 million and $560 million, equivalent to growth of about 21% at the midpoint. For the first quarter of fiscal 2027, it set a revenue range of $130 million to $132 million, with expected year-over-year growth of about 26% at the midpoint. The outlook follows 15 consecutive quarters of sequential growth and puts continued revenue growth at the top of the new fiscal year's test. The company announced an agreement on September 16 with Lilly's TuneLab platform to provide antibody characterization data services in support of artificial intelligence models for drug discovery. It is scheduled to hold its fourth-quarter earnings call on November 12 at 8:00 a.m. Eastern time and expects to file its annual Form 10-K report on November 16.